OptiNose Inc (NAS:OPTN)
$ 1.17 0.06 (5.41%) Market Cap: 132.26 Mil Enterprise Value: 205.21 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

OptiNose Inc To Discuss ReOpen1 Topline Results Call Transcript

Mar 07, 2022 / 09:15PM GMT
Release Date Price: $2.75 (+1.10%)
Operator

Good day, and thank you for standing by. Welcome to the ReOpen1 Top Line Results Conference Call. (Operator Instructions)

Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President of Investor Relations. Please go ahead.

Jonathan Neely
OptiNose, Inc. - VP of IR & Business Operations

Good afternoon, and thank you for joining us today as we review the top line results from the XHANCE ReOpen1 Phase III clinical trial. I'm joined today by our CEO, Peter Miller; our President and Chief Operating Officer, Ramy Mahmoud; our Chief Commercial Officer, Vic Clavelli; our Senior Vice President of Clinical Development and Medical Affairs, John Messina; and our CFO, Keith Goldan. During this call, we will refer to slides that can be viewed on our website, optinose.com, in the Investors section.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot